NMDP Launches Minority Cord Blood Recruitment Initiative

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

MINNEAPOLIS-Give Life Twice. That’s the message behind a new National Marrow Donor Program (NMDP) pilot project designed to increase the number of minority umbilical cord blood units listed on the NMDP Registry. Patients of minority race and ethnicity are less likely than Caucasians to find a matched donor in the Registry, the NMDP said in a press release. The NMDP’s goal is to collect 2,000 units of cord blood from African-American, Hispanic/Latino, and Asian/Pacific Islander donors.

MINNEAPOLIS—Give Life Twice. That’s the message behind a new National Marrow Donor Program (NMDP) pilot project designed to increase the number of minority umbilical cord blood units listed on the NMDP Registry. Patients of minority race and ethnicity are less likely than Caucasians to find a matched donor in the Registry, the NMDP said in a press release. The NMDP’s goal is to collect 2,000 units of cord blood from African-American, Hispanic/Latino, and Asian/Pacific Islander donors.

Four NMDP Cord Blood Banks are participating in the project: Bonfils Cord Blood Services, collecting units in Denver, Boulder, and Colorado Springs, Colorado; Children’s Hospital of Orange County Cord Blood Bank, collecting units in Orange County, California; LifeCord, collecting units in Montgomery, Alabama and Gainesville, Florida; and St. Louis Cord Blood Bank, collecting units in the greater St. Louis, Missouri area.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
Related Content